BIOMARIN PHARMACEUTICAL INC Debt Conversion, Converted Instrument, Amount
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2020-02-27
- BIOMARIN PHARMACEUTICAL INC debt conversion, converted instrument, amount for the quarter ending 2018-12-31 was $0.00.
- BIOMARIN PHARMACEUTICAL INC debt conversion, converted instrument, amount for the quarter ending 2018-09-30 was $0.00.
- BIOMARIN PHARMACEUTICAL INC debt conversion, converted instrument, amount for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC debt conversion, converted instrument, amount for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC debt conversion, converted instrument, amount for fiscal 2019 was $0.00.
- BIOMARIN PHARMACEUTICAL INC debt conversion, converted instrument, amount for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- BIOMARIN PHARMACEUTICAL INC debt conversion, converted instrument, amount for fiscal 2017 was $22.48M, a 151.76% increase from fiscal 2016.
- BIOMARIN PHARMACEUTICAL INC debt conversion, converted instrument, amount for fiscal 2016 was $8.93M, a 2.02% decline from fiscal 2015.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month | Debt Conversion, Converted Instrument, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-27 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $0.00 10-Q · filed 2018-10-26 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-03 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $22.48M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $22.48M 10-Q · filed 2018-10-26 | |||
| 2017-06-30 | $22.48M 10-Q · filed 2018-08-03 | ||||
| 2016-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $1.99M derived: sum of 2 quarters · filed 2019-02-28 | $8.93M 10-K · filed 2019-02-28 | ||
| 2016-09-30 | $1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $8.92M 10-Q · filed 2017-10-31 | |||
| 2016-06-30 | $6.94M 10-Q · filed 2017-08-02 | ||||
| 2015-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $979.00K derived: sum of 2 quarters · filed 2018-02-26 | $979.00K derived: sum of 3 quarters · filed 2018-02-26 | $9.11M 10-K · filed 2018-02-26 | |
| 2015-09-30 | $824.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $824.00K derived: sum of 2 quarters · filed 2016-11-03 | $8.96M 10-Q · filed 2016-11-03 | $13.80M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $8.13M 10-Q · filed 2016-08-08 | $12.97M derived: sum of 3 quarters · filed 2017-02-27 | $12.97M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2015-03-31 | $8.13M 10-Q · filed 2016-05-02 | $12.97M derived: sum of 2 quarters · filed 2017-02-27 | $12.97M derived: sum of 3 quarters · filed 2017-02-27 | $29.46M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2014-12-31 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $4.84M derived: sum of 2 quarters · filed 2017-02-27 | $21.32M derived: sum of 3 quarters · filed 2017-02-27 | $21.32M 10-K · filed 2017-02-27 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $16.48M derived: sum of 2 quarters · filed 2015-11-02 | $16.48M 10-Q · filed 2015-11-02 | $29.98M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-30 | $16.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $16.48M 10-Q · filed 2015-08-05 | $29.98M derived: sum of 3 quarters · filed 2016-02-29 | $61.50M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-02 | $13.50M derived: sum of 2 quarters · filed 2016-02-29 | $45.02M derived: sum of 3 quarters · filed 2016-02-29 | $45.04M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2013-12-31 | $13.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $45.02M derived: sum of 2 quarters · filed 2016-02-29 | $45.04M derived: sum of 3 quarters · filed 2016-02-29 | $283.32M 10-K · filed 2016-02-29 | $286.08M 10-K · filed 2014-02-26 |
| 2013-09-30 | $31.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $31.54M derived: sum of 2 quarters · filed 2014-10-28 | $269.82M 10-Q · filed 2014-10-28 | $269.92M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $238.30M 10-Q · filed 2014-07-31 | $238.41M derived: sum of 3 quarters · filed 2015-03-02 | $238.41M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-03-31 | $238.28M 10-Q · filed 2014-05-02 | $238.38M derived: sum of 2 quarters · filed 2015-03-02 | $238.38M derived: sum of 3 quarters · filed 2015-03-02 | $238.38M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2012-12-31 | $105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $105.00K derived: sum of 2 quarters · filed 2015-03-02 | $105.00K derived: sum of 3 quarters · filed 2015-03-02 | $105.00K 10-K · filed 2015-03-02 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $0.00 derived: sum of 2 quarters · filed 2013-10-28 | $0.00 10-Q · filed 2013-10-28 | ||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-29 | $0.00 10-Q · filed 2013-07-29 | |||
| 2012-03-31 | $0.00 10-Q · filed 2013-04-29 | ||||
| 2011-12-31 | $29.19M 10-K · filed 2014-02-26 | ||||
| 2010-12-31 | $119.56M 10-K · filed 2013-02-26 | ||||
| 2009-12-31 | $0.00 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |